Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Equity Income (2021 - 2024)

Historic Equity Income for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q2 2024 value amounting to -$6000.0.

  • Tarsus Pharmaceuticals' Equity Income fell 14000.0% to -$6000.0 in Q2 2024 from the same period last year, while for Dec 2024 it was -$591000.0, marking a year-over-year decrease of 32818.53%. This contributed to the annual value of -$591000.0 for FY2024, which is 32818.53% down from last year.
  • According to the latest figures from Q2 2024, Tarsus Pharmaceuticals' Equity Income is -$6000.0, which was down 14000.0% from -$585000.0 recorded in Q1 2024.
  • In the past 5 years, Tarsus Pharmaceuticals' Equity Income registered a high of $420000.0 during Q4 2023, and its lowest value of -$591000.0 during Q4 2021.
  • In the last 4 years, Tarsus Pharmaceuticals' Equity Income had a median value of -$65000.0 in 2023 and averaged -$108272.7.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Equity Income surged by 62413.79% in 2023, and later tumbled by 80000.0% in 2024.
  • Over the past 4 years, Tarsus Pharmaceuticals' Equity Income (Quarter) stood at -$591000.0 in 2021, then surged by 109.81% to $58000.0 in 2022, then skyrocketed by 624.14% to $420000.0 in 2023, then plummeted by 101.43% to -$6000.0 in 2024.
  • Its last three reported values are -$6000.0 in Q2 2024, -$585000.0 for Q1 2024, and $420000.0 during Q4 2023.